Press Room

    Back

    Press Release - August 05, 2003

    Pheromone Sciences Signs Chinese Distribution Agreement


    Toronto, Ontario (August 5, 2003) - Pheromone Sciences Corp. (TSX Venture: PHS), a Toronto based biotech company and the developer of the Fertilit�©- OVâ�¢ monitoring device with proprietary technology in the field of non-invasive fertility and ovulation detection is pleased to announce that it has entered into a long-term definitive distribution and licensing agreement with Ningxia St Edenweiss.

    Under the agreement, Ningxia St Edenweiss, a public company whose shares are traded on China's Shenzhen Stock Exchange (symbol 000982) has obtained marketing and distribution rights for Pheromone's Fertilit�©-OV monitor in China, Hong Kong, Macao and Taiwan. Ningxia St Edenweiss is a manufacturing and marketing company with well-established relationships throughout the Chinese medical community. Pheromone shall receive upfront, milestone and royalty payments typical of a transaction of this nature.

    Ningxia St. Edenweiss will immediately institute the filing process for Chinese regulatory approval with product approval expected to be complete within 12 months time.

    "This relationship with Pheromone Sciences is a clear demonstration of Ningxia St. Edenweiss's ability and capacity to market new and innovative technologies," stated Ningxia St. Edenweiss Chairman Mr. Hou Yuqian. "We look forward to introducing the Fertilit�©- OV monitor as well as other new medical devices into this growing marketplace."

    "The completion of this agreement represents a significant milestone for Pheromone Sciences while contributing to the health care needs of couples seeking help in conception", stated Christopher Neuman, President and CEO of Pheromone. "We are confident that the Fertilit�©- OV monitor will have an equally positive response in other markets throughout the world.

    The Fertilit�©-OV monitor is a fertility cycle monitoring device for the consumer and professional medical market and provides a reliable "predictive" approach to natural, cycle-based family planning. The Fertilit�©- OV monitor is a non-invasive method of predicting the fertility window and ovulation date through the measurements of perspiration ion changes on the surface of the skin through a unique combination of bio-sensing and computer technologies These changes in female perspiration allow for the prediction of ovulation up to 4 days before the ovulation day.

    A US based party, previously reported in the notes to the company's financial statements as having provided a non- refundable standby fee has determined that the product is not a suitable strategic fit with their current business model at this time. Efforts remain ongoing with other out-licensing prospects both in the US and other jurisdictions.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

    Back



    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required




Latest Video and Presentation


Sernova Fact Sheet - / September 11, 2017 Open


Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →